ArticlePathogens (Basel, Switzerland)2021
SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.
Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients.Scientific reports · 2025Article
- Clinical Significance of Neutralizing Antibodies in COVID-19: Implications for Disease Prognosis.Life (Basel, Switzerland) · 2025Article
- Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Prevalence of SARS-CoV-2 Antibodies in Kosovo-Wide Population-Based Seroepidemiological Study.Influenza and other respiratory viruses · 2024Article
- Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.European journal of pediatrics · 2024Article
- Editorial for the Topical Collection "SARS-CoV-2 Infection and COVID-19 Disease".Pathogens (Basel, Switzerland) · 2024Article
- Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals.Open forum infectious diseases · 2023Article
- Review
- Detection of SARS-CoV-2 Antibodies: Comparison of Enzyme Immunoassay, Surrogate Neutralization and Virus Neutralization Test.Antibodies (Basel, Switzerland) · 2023Article
- Article
- SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.Viruses · 2022Article
- Article
- Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021.Nature communications · 2022Article
- Waning immunity six months after BioNTech/Pfizer COVID-19 vaccination among nursing home residents in Zagreb, Croatia.Croatian medical journal · 2021Article
- SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021.Medicina (Kaunas, Lithuania) · 2021Article
- Emerging Trends in the Epidemiology of COVID-19: The Croatian 'One Health' Perspective.Viruses · 2021Review
- Impact of COVID-19 on life expectancy at birth in India: a decomposition analysis.BMC public health · 2021Article
- Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients.Biochemia medica · 2021Article
- The Emergence of SARS-CoV-2 within the Dog Population in Croatia: Host Factors and Clinical Outcome.Viruses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus with a pandemic spread. So far, a total of 349,910 SARS-CoV-2 cases and 7687 deaths were reported in Croatia. We analyzed the seroprevalence and neutralizing (NT) antibody response in the Croatian general population after the first (May-July 2020) and second (December 2020-February 2021) pandemic wave. Initial serological testing was performed using a commercial ELISA, with confirmation of reactive samples by a virus neutralization test (VNT). A significant difference in the overall seroprevalence rate was found after the first (ELISA 2.2%, VNT 0.2%) and second waves (ELISA 25.1%, VNT 18.7%). Seropositive individuals were detected in all age groups, with significant differences according to age. The lowest prevalence of NT antibodies was documented in the youngest (<10 years; 16.1%) and the oldest (60-69/70+ years; 16.0% and 12.8%, respectively) age groups. However, these age groups showed the highest median NT titers (32-64). In other groups, seropositivity varied from 19.3% to 21.5%. A significant weak positive correlation between binding antibody level as detected by ELISA and VNT titer (rho = 0.439,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.